Eton Pharmaceuticals

ETON

50.1700.34% ( +0.170 )

Closed: Oct 26, 16:00:00 (EDT)

Q2 FY2026 EarningsQ2 FY26 delivered a comprehensive beat against consensus, characterized by record revenue of $37.6M (+99% YoY) vs. $27.1M expected. Diluted GAAP EPS of $0.35 significantly outperformed the $0.11 consensus mean, while Adjusted EBITDA margins reached a robust 43%. Management significantly raised FY26 revenue guidance to >$145M (from >$120M), far exceeding the prior market outlook.

Financial report interval: 2026.03.30 - 2026.06.30

Overview: Eton Pharmaceuticals(ETON) the Revenue is 37.59 M (+98.59%), Beat estimate;the EBIT is 12.79 M (+967.4%), Beat estimate;the EPS is 0.35 (+450%), Beat estimate.

Actual

YoY

Estimate

YoY

Vs estimate

YoY

RevenueExceed expectations

0.04B98.59%

0.03B43.27%

+0.01B55.32%

EBITExceed expectations

0.01B967.39%

0.00B389.15%

+0.01B578.24%

EPSExceed expectations

0.35450.00%

0.105205.00%

+0.2450245.00%

Upcoming earnings report - Q3 FY2026

Available dateNov 12, 2026

Estimate Revenue$42.21 M

Estimate EBIT$12.21 M

Estimate EPS$0.3125

Revenue

ActualEstimateUnit: USD

Quarterly

EBIT

ActualEstimateUnit: USD

Quarterly

Net income

ActualEstimateUnit: USD

Quarterly

EPS

ActualEstimateUnit: USD

Quarterly